- Home
- Industry Reports
- Diagnostics
- Healthcare
- Middle East & Africa Preventive Vaccines Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Preventative vaccines are administered to a person who is free of the targeted infection. By introducing a part of the virus or an inactive virus (which acts as a decoy) into the body, the immune system reacts by producing antibodies. If years later, the virus enters the organism, these antibodies will recognise and destroy it.
The Middle East & Africa Preventive Vaccines Market Segments Size & Growth:
The Middle East & Africa preventive vaccines market size is projected to reach approximately $28 billion by the end of 2024 with a CAGR of close to 6.6% from $20 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Huge market demand, Higher profitability and improved technology, Government funded projects and Associations, Increasing demand, and a higher onset of diseases. However, High regulatory intervention and cost and Increasing demand for cost-effective vaccines are thereby hampering the market growth.
The Middle East & Africa Preventive Vaccines Market Segments Share:
The Middle East & Africa, preventive vaccines market, is segmented based on the type of vaccines and application. The segment based on the type of vaccine includes live, attenuated vaccine, inactivated vaccines, subunit vaccine, toxoid vaccines, conjugate vaccines, DNA vaccine, and recombinant vector vaccine. Among them, the conjugate segment is expected to account for the most significant share of the vaccines market. The growth in this market is mainly driven by increasing investments by the government of developing countries and rising prevalence of infectious diseases. The market segment based on applications has been further subdivided into pediatric vaccine and adult vaccine. The pediatric vaccines include pneumococcal vaccine, varicella vaccine, combination vaccines (Bivalent, trivalent, tetravalent, and pentavalent vaccines), MMR, poliovirus, hepatitis, HIB, and other pediatric vaccines. The segment on adult vaccines includes influenza, cervical cancer, hepatitis, zoster, and other adult vaccines. By Geography, Africa is projected to dominate the market with the most significant share and the growth in the Middle East & Africa economies is mainly attributed because of huge profit margins and growth prospects.
The Middle East & Africa Preventive Vaccines Market Trends:
- R&D Activities and Commercial Prospects begins by dealing with the significant task of vaccines: prevention of infectious diseases. A thorough overview of vaccine-preventable diseases is given, with a particular focus on human immunodeficiency virus (HIV), hepatitis C, and influenza.
- In early 2016, Pfizer joined the Human Vaccines Project, a public-private consortium that aims to identify human immune responses associated with optimal vaccine protection.
The Middle East & Africa Preventive Vaccines Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Novartis AG
- Johnson and Johnson
- MedImmune, LLC
- Pfizer, Inc.
- Sanofi Pasteur.
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.14 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
5. Middle East & Africa Preventive Vaccines Market- By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
6. Middle East & Africa Preventive Vaccines Market-By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
7. Middle East & Africa Preventive Vaccines Market – By Country
7.1.Introduction
7.2. Africa
7.3.Middle East
8. Company Profiles
8.1 GlaxoSmithKline
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc
8.6 Novartis AG
8.7 Johnson and Johnson,
8.8 MedImmune, LLC
8.9 Pfizer, Inc
8.10. Sanofi Pasteur
9. Middle East & Africa Preventive Vaccines Market – Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,991.88 - €6,639.62
- INR: ₹180,043.09 - ₹600,143.64
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,706.75 - £5,689.16
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Preventative vaccines are administered to a person who is free of the targeted infection. By introducing a part of the virus or an inactive virus (which acts as a decoy) into the body, the immune system reacts by producing antibodies. If years later, the virus enters the organism, these antibodies will recognise and destroy it.
The Middle East & Africa Preventive Vaccines Market Segments Size & Growth:
The Middle East & Africa preventive vaccines market size is projected to reach approximately $28 billion by the end of 2024 with a CAGR of close to 6.6% from $20 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Huge market demand, Higher profitability and improved technology, Government funded projects and Associations, Increasing demand, and a higher onset of diseases. However, High regulatory intervention and cost and Increasing demand for cost-effective vaccines are thereby hampering the market growth.
The Middle East & Africa Preventive Vaccines Market Segments Share:
The Middle East & Africa, preventive vaccines market, is segmented based on the type of vaccines and application. The segment based on the type of vaccine includes live, attenuated vaccine, inactivated vaccines, subunit vaccine, toxoid vaccines, conjugate vaccines, DNA vaccine, and recombinant vector vaccine. Among them, the conjugate segment is expected to account for the most significant share of the vaccines market. The growth in this market is mainly driven by increasing investments by the government of developing countries and rising prevalence of infectious diseases. The market segment based on applications has been further subdivided into pediatric vaccine and adult vaccine. The pediatric vaccines include pneumococcal vaccine, varicella vaccine, combination vaccines (Bivalent, trivalent, tetravalent, and pentavalent vaccines), MMR, poliovirus, hepatitis, HIB, and other pediatric vaccines. The segment on adult vaccines includes influenza, cervical cancer, hepatitis, zoster, and other adult vaccines. By Geography, Africa is projected to dominate the market with the most significant share and the growth in the Middle East & Africa economies is mainly attributed because of huge profit margins and growth prospects.
The Middle East & Africa Preventive Vaccines Market Trends:
- R&D Activities and Commercial Prospects begins by dealing with the significant task of vaccines: prevention of infectious diseases. A thorough overview of vaccine-preventable diseases is given, with a particular focus on human immunodeficiency virus (HIV), hepatitis C, and influenza.
- In early 2016, Pfizer joined the Human Vaccines Project, a public-private consortium that aims to identify human immune responses associated with optimal vaccine protection.
The Middle East & Africa Preventive Vaccines Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Novartis AG
- Johnson and Johnson
- MedImmune, LLC
- Pfizer, Inc.
- Sanofi Pasteur.
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.14 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
5. Middle East & Africa Preventive Vaccines Market- By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
6. Middle East & Africa Preventive Vaccines Market-By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
7. Middle East & Africa Preventive Vaccines Market – By Country
7.1.Introduction
7.2. Africa
7.3.Middle East
8. Company Profiles
8.1 GlaxoSmithKline
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc
8.6 Novartis AG
8.7 Johnson and Johnson,
8.8 MedImmune, LLC
8.9 Pfizer, Inc
8.10. Sanofi Pasteur
9. Middle East & Africa Preventive Vaccines Market – Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.